Evaluation of Remdesivir and Hydroxychloroquine on Viral Clearance in Covid-19 Patients: Results from the NOR-Solidarity Randomised Trial
Evaluation of remdesivir and hydroxychloroquine on viral clearance in Covid-19 patients: Results from the NOR-Solidarity Randomised Trial Andreas Barratt-Due1,2,9,*, Inge Christoffer Olsen3, Katerina Nezvalova Henriksen4,5, Trine Kåsine1,9, Fridtjof Lund-Johansen2,6, Hedda Hoel7,9,10, Aleksander Rygh Holten8,9, Anders Tveita11, Alexander Mathiessen12, Mette Haugli13, Ragnhild Eiken14, Anders Benjamin Kildal15, Åse Berg16, Asgeir Johannessen9,17, Lars Heggelund18,19, Tuva Børresdatter Dahl1,10, Karoline Hansen Skåra10, Pawel Mielnik20, Lan Ai Kieu Le21, Lars Thoresen22, Gernot Ernst23, Dag Arne Lihaug Hoff24, Hilde Skudal25, Bård Reiakvam Kittang26, Roy Bjørkholt Olsen27, Birgitte Tholin28, Carl Magnus Ystrøm29, Nina Vibeche Skei30, Trung Tran2, Susanne Dudman9,39, Jan Terje Andersen9,31, Raisa Hannula32, Olav Dalgard9,33, Ane-Kristine Finbråten7,34, Kristian Tonby9,35, Bjorn Blomberg36,37, Saad Aballi38, Cathrine Fladeby39, Anne Steffensen9, Fredrik Müller9,39, Anne Ma Dyrhol-Riise9,35, Marius Trøseid9,40 and Pål Aukrust9,10,40 on behalf of the NOR-Solidarity study group# 1Division of Critical Care and Emergencies, Oslo University Hospital, 0424 Oslo, Norway 2Division of laboratory Medicine, Dept. of Immunology, Oslo University Hospital, 0424 Oslo, Norway 3Department of Research Support for Clinical Trials, Oslo University Hospital, 0424 Oslo, Norway 4Department of Haematology, Oslo University Hospital, 0424 Oslo, Norway 5Hospital Pharmacies, South-Eastern Norway Enterprise, 0050 Oslo, Norway 6ImmunoLingo Covergence Centre, University
[Show full text]